Apomorphine

Subscribe to Selected New Research on Apomorphine

1588 relevant articles (104 outcomes, 139 trials/studies) found for this Bio-Agent

Description: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.

Also Known As:

Aguettant Brand of Apomorphine Hydrochloride; Apokinon; Apomorphin-Teclapharm; Apomorphine Chloride; Apomorphine Hydrochloride, Anhydrous; Apomorphine Hydrochloride, Hemihydrate; Britaject; Britannia Brand of Apomorphine Hydrochloride; Teclapharm Brand of Apomorphine Hydrochloride; Anhydrous Apomorphine Hydrochloride; Apomorphin Teclapharm; ApomorphinTeclapharm; Chloride, Apomorphine; Hemihydrate Apomorphine Hydrochloride; Hydrochloride, Anhydrous Apomorphine; Hydrochloride, Hemihydrate Apomorphine; 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)-

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 25

Alkaloids: 691

Benzylisoquinolines: 3

2-Ring Heterocyclic Compounds

Isoquinolines: 18

Benzylisoquinolines: 3

Heterocyclic Compounds with 4 or More Rings

Experts

1.	Trenkwalder, C: 4 articles (04/2008 - 02/2001)
2.	Odin, P: 3 articles (04/2008 - 02/2001)
3.	Stacy, Mark: 3 articles (01/2008 - 09/2006)
4.	Paulus, Walter: 3 articles (08/2007 - 12/2004)
5.	Trenkwalder, Claudia: 3 articles (08/2007 - 12/2004)
6.	Happe, Svenja: 3 articles (08/2007 - 12/2004)
7.	Morgante, L: 3 articles (04/2006 - 10/2003)
8.	Antonini, A: 3 articles (04/2006 - 10/2003)
9.	Lees, Andrew J: 3 articles (02/2005 - 11/2002)
10.	Stocchi, F: 3 articles (01/2004 - 02/2001)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 09/01/2000 - "Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use." 01/01/2008 - "In three pivotal, randomized, placebo-controlled trials, subcutaneous apomorphine was effective in acutely treating "off" episodes, significantly improving Unified Parkinson Disease Rating Scale motor scores and reducing the number of "off" hours per day, with a significantly shorter time to patient-declared onset of relief than placebo. " 02/27/2009 - "The result indicated that combined treatment of neurotrophin-3 gene and neural stem cells had a functional impact on reversing the main symptoms of the Parkinson's disease that significantly reduced apomorphine-induced rotational asymmetry and improved spatial learning ability. " 09/01/1998 - "A statistically significant reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score was seen following active apomorphine during in-office evaluation visits but not following placebo nasal spray. " 09/01/1999 - "If more population data become available, the population pharmacokinetics-pharmacodynamics of apomorphine could be helpful in predicting the clinical effects of apomorphine in the several subgroups of patients with Parkinson's disease." Order ALL the reference details at left...
2.	Erectile Dysfunction 03/01/2002 - "OBJECTIVE: To determine the risk-benefit ratio of a forced dose-escalation regimen (2 to 3 to 4 mg) in a European clinical study evaluating apomorphine sublingual (SL) in treating erectile dysfunction (ED), by evaluating the overall tolerability and efficacy of the regimen compared with placebo in patients with ED, and evaluating efficacy by assessing the proportion of successful attempts resulting in sexual intercourse. " 05/01/1998 - "Four of the patients reported erectile dysfunction before beginning apomorphine and two of these report a significant improvement in their sexual function resulting from apomorphine use. " 10/01/2001 - "Sublingual (SL) apomorphine (2 to 6 mg) has been shown to be effective for treatment of male erectile dysfunction. " 08/01/2001 - "The development process for apomorphine SL as an effective treatment for patients with erectile dysfunction has been somewhat unusual. " 01/01/2001 - "Apomorphine SL (Ixense, Uprima) is a new oral medication shown to be effective in the treatment of erectile dysfunction. " Order ALL the reference details at left...
3.	Vomiting 01/01/1980 - "Octoclothepin possesses high cataleptogenic and anti-apomorphine activities in rats; it is able to exert full protection against apomorphine-induced emesis in dogs after the dose of 0.1 mg kg-1 s.c. " 07/01/1997 - "Neither of the ginger extract was effective against apomorphine-induced emesis. " 10/01/2008 - "OBJECTIVE: To evaluate the safety and efficacy of an ocular insert designed to provide controlled release of apomorphine for the induction of emesis in dogs. " 10/01/2008 - "Safety and efficacy of an ocular insert for apomorphine-induced emesis in dogs." 01/01/2003 - "[Comparative experimental study of antiemetic action of latranum in radiation-induced vomiting and vomiting caused by apomorphine]" Order ALL the reference details at left...
4.	Dyskinesias (Dyskinesia) 02/01/1994 - "Apomorphine was effective in reducing the duration of diphasic dyskinesias at doses higher than the threshold doses necessary to induce an "on" phase (mean increase: 43%). " 02/01/1994 - "In two patients, apomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon. " 03/01/2005 - "Animals receiving apomorphine rods showed improved motor function ('ON' state) within 1 day of implantation, and remained continually 'ON' for the duration of treatment (up to 6 months) without developing dyskinesias. " 02/01/1986 - "Apomorphine has been reported to have therapeutic effects in previous studies but, we were not able to confirm any significant and specific differences in psychotic symptoms or tardive dyskinesia scores with apomorphine administration, compared with placebo. " 11/01/1979 - "Previous studies comparing the magnitude of these responses in schizophrenics and controls suggest that many acute (and some chronic) schizophrenics have exaggerated hGH responses; many chronic schizophrenics (and patients with tardive dyskinesia) have blunted hGH responses to apomorphine, and possibly blunted PRL responses. " Order ALL the reference details at left...
5.	Seizures (Seizure) 07/01/1981 - "The evaluation of 2c on audiogenic seizures in mice, in the protection against paroxysimal EEG and myoclonic response to photic stimulation in the baboon, revealed a similar pharmacological profile in comparison to NPA and apomorphine, with TNPA showing a prolonged duration of action in abolishing myoclonic response to photic stimulation in the baboon." 12/07/1979 - "While both drugs stimulated the brain by prolonging the oligemia-induced seizures in the caudate nucleus and in the cerebral cortex, only apomorphine improved the pO2 distribution in the cortical tissue after 120 min oligemia. " 09/01/1998 - "ECS in rats has several robust behavioral effects, including enhancement of apomorphine-induced stereotypy, reduction of immobility time in the Porsolt swim test, and increases in seizure threshold for subsequent stimulation. " 06/01/1994 - "Apomorphine, a mixed D1/D2/D3 agonist, delayed seizure onset at 100-500 pmol, but not at higher doses. " 10/01/1993 - "Apomorphine (0.02-0.5 mg/kg, sc), a D1/D2 agonist, showed proconvulsant effect on electrically-induced convulsions. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Dopamine Agonists (Dopamine Agonist)
3.	Haloperidol (Haldol)
4.	Dopamine (Intropin)
5.	Dopamine Receptors (Dopamine Receptor)
6.	Metoclopramide (Reglan)
7.	Domperidone (Domperidon)
8.	Sulpiride (neogama)
9.	Chlorpromazine (Thorazine)
10.	Pimozide (Orap)

Related Therapies and Procedures

1.	Deep Brain Stimulation
2.	Injections
3.	Subcutaneous Injections
4.	Subcutaneous Infusions
5.	Aftercare (After-Treatment)

Best Treatments:
Research Summary Report
on Parkinson Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1228 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>